Drug Profile
KN 041
Alternative Names: KN-041Latest Information Update: 28 Jun 2019
Price :
$50
*
At a glance
- Originator Alphamab
- Developer Jiangsu Alphamab Biopharmaceuticals
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for research development in Cancer in China
- 07 May 2015 Early research in Cancer in China (unspecified route)